ALK and lung adenocarcinoma: The global real-world study GLASS, which analyzed the efficacy of lorlatinib in 106 ALK-positive advanced lung adenocarcinoma patients, showed an ORR of 62% and a DCR of 88% in patients with brain metastasis (26).